{"schema":"sb.node.v1","id":"sb:e/85a46c3fe31041288a0a56c9","kind":"entity","label":{"text":"eli lilly","locale":"en"},"identity":{"anchor":"label:en:eli lilly","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T21:52:38.794589+00:00","snapshot":"deploy 42fcb912508e16b96962a1bf0a5ae2df232e259a"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":276,"separatePublishers":89,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-06","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.283: about 72% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma"],"activeDays":40,"assertions":{"regulatory-approval":24,"launch-release":13,"utterance":8,"acquisition":5,"ipo-listing":5,"price-threshold":4}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/88f2eba6f0215e98f5b7a64b","kind":"observation","label":"European Medical Journal · 2026-10-03 · Forghorn slashes workforce by 40% after deal with Eli Lilly ends","url":"https://www.emjreviews.com/emj-gold/news/forghorn-slashes-workforce-by-40-after-deal-with-eli-lilly-ends/"},{"id":"sb:o/0566e313c0d683a028bbb5f6","kind":"observation","label":"Endpoints News · 2026-10-03 · Eli Lilly’s best-ever weight loss data; Sanofi, Regeneron re-up for $1B upfront; and more","url":"https://endpoints.news/eli-lillys-best-ever-weight-loss-data-sanofi-regeneron-re-up-for-1b-upfront-and-more/"},{"id":"sb:o/b6399bf5e0b34644440222e3","kind":"observation","label":"UNKNOWN (source name missing from feed) · 2026-10-03 · Eli Lilly, Purdue to share field learnings on human robot interaction at RoboBusiness","url":"https://www.therobotreport.com/eli-lilly-purdue-to-share-field-learnings-on-human-robot-interaction-at-robobusiness/"},{"id":"sb:o/b57718540add577e780cf097","kind":"observation","label":"STAT News · 2026-10-01 · STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial","url":"https://www.statnews.com/2026/09/30/eli-lilly-zepbound-amylin-combination-drug-study/?utm_campaign=rss"},{"id":"sb:o/3568674abae3447c80809e91","kind":"observation","label":"Fierce Pharma · 2026-09-29 · Eli Lilly's new initiative will take GLP-1s to lower-income nations","url":"https://www.fiercepharma.com/pharma/lillys-new-initiative-will-take-glp-1s-lower-income-nations"},{"id":"sb:o/90f8adab7cc9396288246572","kind":"observation","label":"PR Daily · 2026-09-28 · The Scoop: Eli Lilly defends presence at Vogue World","url":"https://www.prdaily.com/the-scoop-eli-lilly-defends-presence-at-vogue-world/"},{"id":"sb:o/f53fc1a6ee4e50ac99ded5d2","kind":"observation","label":"24/7 Wall St. · 2026-09-28 · Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come","url":"https://247wallst.com/investing/2026/09/28/eli-lilly-wavered-over-the-last-month-one-of-wall-streets-biggest-banks-says-35-gains-still-to-come/"},{"id":"sb:o/e1a4fee963ec2daa68823e43","kind":"observation","label":"Fierce Pharma · 2026-09-26 · Eli Lilly blasted for ‘promotional and emotive’ language in GLP-1 press release","url":"https://www.fiercepharma.com/marketing/eli-lilly-blasted-promotional-and-emotive-language-glp-1-press-release"},{"id":"sb:o/16f787bc16f686f0484a62f1","kind":"observation","label":"Fierce Pharma · 2026-09-24 · Eli Lilly CEO touts 70% share as Medicare GLP-1 program reaches 700K seniors","url":"https://www.fiercepharma.com/pharma/eli-lilly-ceo-touts-70-share-medicare-glp-1-program-reaches-700k-seniors"},{"id":"sb:o/060ab0f8b8b0aa1e6dface7b","kind":"observation","label":"ConstructConnect News · 2026-09-23 · Eli Lilly Breaks Ground on $6.5B Houston Pharmaceutical Manufacturing Facility","url":"https://news.constructconnect.com/eli-lilly-breaks-ground-on-6.5b-houston-pharmaceutical-manufacturing-facility"}],"cursor":"c1.eyJpZCI6InNiOmUvODVhNDZjM2ZlMzEwNDEyODhhMGE1NmM5IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDIxOjUyOjM4Ljc5NDU4OSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":11,"byKind":{"claim":1,"co-mentioned":10},"items":[{"id":"sb:p/82601684a4fd4e3332f14a9d","kind":"claim","label":"With FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL — corroborated","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with glp-1 (89 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/780e192cbb11a0ba2d140505"},{"kind":"relation","label":"co-mentioned with fda (79 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/71324105fbda62f5fde99cb9"},{"kind":"relation","label":"co-mentioned with ai (73 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9c21ab461cbc4a7940c5b532"},{"kind":"relation","label":"co-mentioned with novo nordisk (50 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/73e95c35dd32f4410d3327d7"},{"kind":"relation","label":"co-mentioned with trump (42 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/012fefc63efeb3b5a4085c38"},{"kind":"relation","label":"co-mentioned with united states (39 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ac3f5a7f6581ed3ea89e5e52"},{"kind":"relation","label":"co-mentioned with china (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4b144d3ab70932c3528bd6d1"},{"kind":"relation","label":"co-mentioned with zepbound (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/bd43652248bcbe78a0b864d7"},{"kind":"relation","label":"co-mentioned with novartis (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d7d3f3adc4f766b96328dfc5"}],"cursor":"c1.eyJpZCI6InNiOmUvODVhNDZjM2ZlMzEwNDEyODhhMGE1NmM5IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0wOFQyMTo1MjozOC43OTQ1ODkrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/85a46c3fe31041288a0a56c9","mcp":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\"}","page":"/entity/eli-lilly/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}